Table 2 ORs and 95% CIs for CCL and breast cancer risk among participants with BBD
From: Columnar cell lesions and subsequent breast cancer risk: a nested case-control study
| Â | Cases | Controls | OR (95%CI)* | OR (95%CI)** |
|---|---|---|---|---|
CCL status | Â | Â | Â | Â |
   No CCL | 254 | 1,158 | 1.0 (reference) | 1.0 (reference) |
   CCL | 140 | 448 | 1.44 (1.14, 1.83) | 1.37 (1.06, 1.76) |
CCL status, adjusted for BBD histologic category | Â | Â | Â | Â |
   No CCL | 254 | 1,158 | 1.0 (reference) | 1.0 (reference) |
   CCL | 140 | 448 | 1.20 (0.94, 1.54) | 1.16 (0.89, 1.50) |
Jointly classified BBD/CCL histologic category | Â | Â | Â | Â |
   Nonproliferative, no CCL | 80 | 518 | 1.0 (reference) | 1.0 (reference) |
   Nonproliferative, CCL | 19 | 93 | 1.33 (0.77, 2.29) | 1.24 (0.69, 2.22) |
   Proliferative without atypia, no CCL | 125 | 558 | 1.46 (1.08, 1.99) | 1.38 (1.00, 1.91) |
   Proliferative without atypia, CCL | 74 | 277 | 1.81 (1.27, 2.58) | 1.63 (1.12, 2.38) |
   Atypical hyperplasia, no CCL | 49 | 82 | 4.26 (2.75, 6.59) | 4.04 (2.57, 6.36) |
   Atypical hyperplasia, CCL | 47 | 78 | 4.37 (2.81, 6.81) | 4.20 (2.63, 6.70) |